Am J Blood Res 2011;1(1):90-97
Review Article
Hematopoietic stem cell transplantation in China: current status and prospects
Xiao-Jun Huang
Peking University People’s Hospital, Peking University Institute of Hematology, No. 11 South Street of Xizhimen, Xicheng
District, Beijing 100044, P.R. China.
Received May 15, 2011; accepted May 28, 2011; Epub June 1, 2011; published June 15, 2011
Abstract: During the past four decades, a substantial progress has been made in the field of hematopoietic stem cell
transplantation (HSCT). From July, 2007 to December, 2010, a transplant survey from 42 HSCT units indicates that the types
of transplantation performed are related identical (43%), related mismatched/haploidentical (28%), unrelated donor matched
(11%), unrelated donor mismatched (7%), umbilical cord blood (UCB, 2%) and autologous (9%). The distribution of disease
entities being transplanted in allogeneic settings is acute myeloid leukemia (AML) (34%), acute lymphoblastic leukemia (ALL)
(24%), chronic myeloid leukemia (CML) (20%), myelodysplastic syndrome (MDS) (8%), aplastic anemia (AA) (7%),
mediterranean anemia (MIA) (2%), non-Hodgkin's lymphoma (NHL) (3%), and other diseases (3%). Clinical data from Peking
University Institute of Hematology and other transplant centers suggest that haploidentical transplantation has been a choice
of the best alternative source of stem cells for individual patients without matched sibling donors. A modified donor
lymphocyte infusion (DLI) approach can be safely used for prophylaxis and treatment of leukemia relapse in patients with
advanced leukemia following mismatched transplant. The number of transplants from unrelated donor or related
mismatched/haploidentical donor has increased significantly during recent years. Double UCBT is a promising strategy for
the therapy of hematological disease. In addition, mesenchymal stem cell (MSC) transplantation may be a potential
therapeutic approach for treating systemic lupus erythematosus (SLE). (AJBR1105004).
Keywords: Hematopoietic, blood, stem cell, transplantation, HSCT, China, review
Full Text PDF
Address all correspondence to:
Xiao-Jun Huang, MD
Peking University Institute of Hematology
Peking University People’s Hospital
No 11 Xizhimen South Street
Beijing 100044, China.
Tel: 86-010-88326006
Fax: 86-010-88324577
E-mail: xjhrm@medmail.com.cn
Review Article
Hematopoietic stem cell transplantation in China: current status and prospects
Xiao-Jun Huang
Peking University People’s Hospital, Peking University Institute of Hematology, No. 11 South Street of Xizhimen, Xicheng
District, Beijing 100044, P.R. China.
Received May 15, 2011; accepted May 28, 2011; Epub June 1, 2011; published June 15, 2011
Abstract: During the past four decades, a substantial progress has been made in the field of hematopoietic stem cell
transplantation (HSCT). From July, 2007 to December, 2010, a transplant survey from 42 HSCT units indicates that the types
of transplantation performed are related identical (43%), related mismatched/haploidentical (28%), unrelated donor matched
(11%), unrelated donor mismatched (7%), umbilical cord blood (UCB, 2%) and autologous (9%). The distribution of disease
entities being transplanted in allogeneic settings is acute myeloid leukemia (AML) (34%), acute lymphoblastic leukemia (ALL)
(24%), chronic myeloid leukemia (CML) (20%), myelodysplastic syndrome (MDS) (8%), aplastic anemia (AA) (7%),
mediterranean anemia (MIA) (2%), non-Hodgkin's lymphoma (NHL) (3%), and other diseases (3%). Clinical data from Peking
University Institute of Hematology and other transplant centers suggest that haploidentical transplantation has been a choice
of the best alternative source of stem cells for individual patients without matched sibling donors. A modified donor
lymphocyte infusion (DLI) approach can be safely used for prophylaxis and treatment of leukemia relapse in patients with
advanced leukemia following mismatched transplant. The number of transplants from unrelated donor or related
mismatched/haploidentical donor has increased significantly during recent years. Double UCBT is a promising strategy for
the therapy of hematological disease. In addition, mesenchymal stem cell (MSC) transplantation may be a potential
therapeutic approach for treating systemic lupus erythematosus (SLE). (AJBR1105004).
Keywords: Hematopoietic, blood, stem cell, transplantation, HSCT, China, review
Full Text PDF
Address all correspondence to:
Xiao-Jun Huang, MD
Peking University Institute of Hematology
Peking University People’s Hospital
No 11 Xizhimen South Street
Beijing 100044, China.
Tel: 86-010-88326006
Fax: 86-010-88324577
E-mail: xjhrm@medmail.com.cn
| AJBR Copyright © 2011-present, All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711, USA |
 |  |  |  |  |  |  |